Cargando…

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies

BACKGROUND: Reimbursement decisions are conventionally based on evidence from randomised controlled trials (RCTs), which often have high internal validity but low external validity. Real-world data (RWD) may provide complimentary evidence for relative effectiveness assessments (REAs) and cost-effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makady, Amr, van Veelen, Ard, Jonsson, Páll, Moseley, Owen, D’Andon, Anne, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf, Goettsch, Wim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834594/ https://www.ncbi.nlm.nih.gov/pubmed/29214389 http://dx.doi.org/10.1007/s40273-017-0596-z

Ejemplares similares

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study
por: Makady, Amr, et al.
Publicado: (2018)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
por: Schelleman, Hedi, et al.
Publicado: (2015)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level
por: Calabrò, G. E., et al.
Publicado: (2018)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

The Utility of a Rapid Review Evaluation Process to a National HTA Agency
por: Varley, Áine, et al.
Publicado: (2021)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

Use of Surrogate end points in HTA
por: Mangiapane, Sandra, et al.
Publicado: (2009)

Ethics in HTA: Examining the "Need for Expansion"
por: Abrishami, Payam, et al.
Publicado: (2017)

Impact of COVID-19 pandemic on HTA
Publicado: (2020)

Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
por: Kisser, Agnes, et al.
Publicado: (2021)

Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations
por: Yuba, Tania Yuka, et al.
Publicado: (2018)

Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"
por: Gopinathan, Unni, et al.
Publicado: (2020)

Ethical analysis in HTA of complex health interventions
por: Lysdahl, Kristin Bakke, et al.
Publicado: (2016)

HTA assessment of COVID-19 interventions in Ireland
Publicado: (2020)

Hospital-based health technology assessment (HTA) in Finland: a case study on collaboration between hospitals and the national HTA unit
por: Halmesmäki, Esa, et al.
Publicado: (2016)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018)

HTA66 Outcomes Examined in Clinical Trials of Medicines for COVID-19: A Review of Regulatory Agencies' Websites
por: Rojas, P, et al.
Publicado: (2022)

Bibliometrics of NIHR HTA monographs and their related journal articles
por: Royle, Pamela, et al.
Publicado: (2015)

Why not integrate ethics in HTA: identification and assessment of the reasons
por: Hofmann, Bjørn
Publicado: (2014)

Time to publication for NIHR HTA programme-funded studies
por: Chinnery, Fay, et al.
Publicado: (2013)

HTA Implementation Roadmap in Central and Eastern European Countries
por: Kaló, Zoltán, et al.
Publicado: (2016)

Patient advocate perspectives on involvement in HTA: an international snapshot
por: Scott, Anna Mae, et al.
Publicado: (2017)

Worldwide HTA access to ICER's cost-effectiveness models
Publicado: (2020)

HB-HTA as an implementation problem in Polish health policy
por: Gałązka-Sobotka, Małgorzata, et al.
Publicado: (2021)

Living HTA: Automating Health Economic Evaluation with R
por: Smith, Robert A., et al.
Publicado: (2022)

Using HTA and guideline development as a tool for research priority setting the NICE way: reducing research waste by identifying the right research to fund.
por: Sharma, Tarang, et al.
Publicado: (2018)

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
por: Dintsios, C. M., et al.
Publicado: (2019)

HTA Agencies Need Evidence-Informed Deliberative Processes Comment on "Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"
por: Schlander, Michael
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e32id4su4d8lt1s6tdiaqhja62